Who owns BLTE? 13F holders and whale ownership
BLTE is tracked across public portfolios in Whale Analyzer. This page answers who owns BLTE, which top funds are buying BLTE, aggregate disclosed value, and recent position changes based on public data. Joseph Edelman is the largest reported holder at $24M; the top five funds control 100.0% of reported ownership; institutions were net selling last quarter (1 increased, 1 reduced); the stock trades below the aggregate whale cost basis of $152.07. Top tracked holders include Joseph Edelman and Stanley Druckenmiller.
Continue to the live BLTE dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Joseph Edelman 13F portfolio Perceptive Advisors holdings | $24.2M | 152.0K | Reduced |
| Stanley Druckenmiller 13F portfolio Duquesne Family Office holdings | $16.9M | 106.1K | New |
Ownership concentration
Reported ownership of BLTE is highly concentrated across tracked institutions.
- Single largest holder: 58.9% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 2 tracked institutions, 1 reduced, 1 increased. Net positioning is net selling.
- Joseph Edelman — Perceptive Advisors ($24.2M) (▼ 63.3% qoq shares)
- Stanley Druckenmiller — Duquesne Family Office ($16.9M) · avg cost $152.07
Whale cost basis vs current price
The aggregate tracked cost basis is $152.07 versus a current price of $148.73, so BLTE trades below its cost basis (-2.2%). Average unrealized P&L across tracked holders: -6%.
Sector positioning — Other
BLTE sits within the Other sector alongside 670 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live BLTE dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- PRAX whale holders — PRAXIS PRECISION MEDICINES I
- CELC whale holders — CELCUITY INC
- ASND whale holders — ASCENDIS PHARMA A/S
- ROIV whale holders — ROIVANT SCIENCES LTD
- CNTA whale holders — CENTESSA PHARMACEUTICALS PLC
- RYTM whale holders — RHYTHM PHARMACEUTICALS INC
- SYRE whale holders — SPYRE THERAPEUTICS INC
- NUVL whale holders — NUVALENT INC
Learn more in Whale Analyzer Academy
Deepen your read on BLTE with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns BLTE stock?
Whale Analyzer tracks 2 public institutional holders of BLTE with a combined reported value of $41.1M. See the holder table above for the largest tracked positions.
Which top funds are buying BLTE?
Tracked institutions were net selling last quarter — 1 reduced, 1 increased. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is BLTE ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is BLTE above or below the whale cost basis?
The aggregate tracked cost basis is $152.07 versus a current price of $148.73 (-2.2%).
What does 13F ownership mean for BLTE?
Use the interactive BLTE dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.